Serious riskFDA DrugClass I

Tyenne (tocilizumab-aazg) injection recalled for glass particles

Fresenius Kabi USA discovered that Tyenne (tocilizumab-aazg) Injection vials may contain glass particles. The contamination was found during an internal investigation. The affected lot is 16UI07, which expires August 31, 2028.

From the FDA notice · Read the official notice ↗ · All Fresenius Kabi recalls

What to do

  1. If you have received this medication, do not use it.
  2. Contact your healthcare provider or pharmacist immediately for a replacement.
  3. Check your vials for any visible particles before use.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by Fresenius Kabi USA, LLC, Lake Zurich, Illinois, 60047, NDC 65219-594-20.
Sold in
Nationwide
Made for
Adults (0 months and older)

Details

Units affected
4,643 20mL-vials
Illnesses reported
None reported
Manufactured in
3 Corporate Dr, N/A, Lake Zurich, IL, United States
Classification
Class I
Recall number
D-0827-2026

In the FDA's words

Description
Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by Fresenius Kabi USA, LLC, Lake Zurich, Illinois, 60047, NDC 65219-594-20. Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles. Lot: 16UI07, Exp 08/31/2028 Distribution: Nationwide in the USA Affected quantity: 4,643 20mL-vials
Hazard
Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles.

More from Fresenius Kabi

See all

Related topics

GlassParticulateDrugsSold nationwideMore from FDA Drug